Pharming Group N.V. ADS (PHAR)
NASDAQ: PHARHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PHAR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $816.78M
- P/E (TTM)
- 36.06
- Forward P/E
- 64.11
- EPS (TTM)
- $0.32
- Dividend yield
- None
- 52-week range
- 9.11 – 21.34
- Day range
- 11.30 – 11.97
- Volume / Avg
- 10.51K / 21.33K
- Beta
- —
- Shares outstanding
- 70.78M
52-week range
PHAR stock today
Shares of Pharming Group N.V. (PHAR) finished lower on Nov 20 at $11.54, a drop of 5.10% or $0.62 per share, versus the S&P 500's 3.70% decline. Trading was light, with 10.51K shares changing hands, about 49% of the average daily volume. Shares are 45.9% below their 52-week high of $21.34, set on Jan 27, 2026 and 26.7% above the 52-week low of $9.11, near the bottom of the past year's range.
PHAR is down 34.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 29.0%. Pharming Group N.V. trades at 36.1x its trailing twelve-month earnings per share of $0.32. Its forward P/E of 64.1x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Pharming Group N.V.
Company profilePharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kenneth Lynard EMBA, M.Sc.
- Headquarters
- Leiden
- Employees
- 407
- Website
- pharming.com
Financial highlights
Full financialsIn fiscal 2025, Pharming Group N.V. generated $376.1 million in revenue, up 26.6% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $2.9 million, for a net margin of 0.8% versus a median of 6.7% in the prior 5 years. Gross margin was 87.9% (down from 88.1%) and operating margin 6.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $376.13M | $297.20M | $245.32M | $205.62M | $198.87M |
| Growth | +26.56% | +21.15% | +19.30% | +3.39% | -6.27% |
| Net income | $2.85M | $-11.84M | $-10.55M | $13.67M | $16.00M |
| EPS (diluted) | $0.004 | $-0.018 | $-0.016 | $0.019 | $0.023 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$35.70+209.36%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $0.10 vs $0.33
- Surprise
- -69.70%
PHAR news
All PHAR news- Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in LondonGlobeNewswire
- MHRA Approves Pharming Group N.V.’s Joenja as First Treatment Specifically for Children with APDS in the U.K.Nasdaq
- MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.GlobeNewswire
- Pharming: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Pharming (PHAR) Q3 2026 Earnings Call TranscriptNasdaq
- Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberNasdaq
- Pharming Q3 Revenue Jumps 21%, CVID Data Due In NovemberNasdaqPHAR, ET
- Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberGlobeNewswire
Pharming Group N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs PHAR |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs PHAR |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs PHAR |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs PHAR |
| MTRIMentari Therapeutics Inc. | 14.70 | -3.57% | $856.94M | vs PHAR |
| LTGOLatigo Biotherapeutics Inc. | 13.00 | -1.81% | $861.89M | vs PHAR |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs PHAR |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs PHAR |
Indexes, lists and sector
Pharming Group N.V. stock FAQ
What is Pharming Group N.V.'s stock price today?
PHAR last traded at $11.54 as of Nov 20, 4:00 PM EST, down 5.10% on the day. Prices are delayed at least 15 minutes.
What is PHAR's P/E ratio?
PHAR trades at a trailing P/E ratio of 36.06 and a forward P/E of 64.11.
Who is Pharming Group N.V.'s CEO?
Mr. Kenneth Lynard EMBA, M.Sc. is the chief executive officer of Pharming Group N.V. ADS, which has about 407 employees.
What is the PHAR 52-week high?
The 52-week high for PHAR is $21.34 and the 52-week low is $9.11. The stock is currently 45.9% below its high.